about
Integrated oral bioavailability projection using in vitro screening data as a selection tool in drug discovery.Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease.Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans.Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.Pharmacokinetics of the Inhaled Selective Glucocorticoid Receptor Modulator AZD5423 Following Inhalation Using Different Devices.Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease.Rate of change of blood concentrations is a major determinant of the pharmacodynamics of midazolam in rats.Adaptive changes in the pharmacodynamics of midazolam in different experimental models of epilepsy: kindling, cortical stimulation and genetic absence epilepsy.A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia.Effect of amygdala kindling on the central nervous system effects of tiagabine: EEG effects versus brain GABA levels.Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release.Sequential protein and peptide immunoaffinity capture for mass spectrometry-based quantification of total human β-nerve growth factor.The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets.A time scaling approach to develop an in vitro-in vivo correlation (IVIVC) model using a convolution-based technique.A nonlinear mixed effects IVIVC model for multi-release drug delivery systems.A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.Mass balance, metabolic disposition, and pharmacokinetics of a single oral dose of regorafenib in healthy human subjects.Mechanism-based modeling of functional adaptation upon chronic treatment with midazolam.Mechanism-based modeling of adaptive changes in the pharmacodynamics of midazolam in the kindling model of epilepsy.Pharmacokinetic-pharmacodynamic modelling of tiagabine CNS effects upon chronic treatment in rats: lack of change in concentration-EEG effect relationship.Prognostic Significance of Periodic Acid-Schiff-Positive Patterns in Primary Breast Cancer and its Lymph Node MetastasesLiquid chromatographic determination of the adenosine receptor agonist CGS 21680 in blood using on-line solid-phase extraction on a phenylboronic acid support and fluorescence detectionCharacterizing systemic exposure of inhaled drugs: application to the long-acting β2-agonist PF-00610355A single-dose, open-label, parallel, randomized, dose-proportionality study of paliperidone after intramuscular injections of paliperidone palmitate in the deltoid or gluteal muscle in patients with schizophreniaEffect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady-statePharmacokinetic profile after multiple deltoid or gluteal intramuscular injections of paliperidone palmitate in patients with schizophreniaThe effect of gastrectomy on regorafenib exposure and progression-free survival in patients with advanced gastrointestinal stromal tumoursA phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
P50
Q30886901-9738E278-639B-442E-A06D-989EBD3B06D8Q34322908-F6A4AA0A-9FD5-492C-BC4C-A047D829568BQ34742844-B6401E1B-E07E-4084-93B8-6D03399FB444Q38761021-0515330C-81C8-4B42-8FAF-F0DFD084BB65Q38915511-6AB43466-CCF5-4E76-8334-A20573A5B779Q39548676-6924038E-B61C-4639-8B25-6EB796C6BAA3Q43191710-A3B190AA-8C47-4B23-B753-B7E3354114F2Q43254164-2E0F64DD-B1D7-48D8-A9F1-415932DDFE13Q43262223-030F2A04-C671-493E-AD9C-FEA0649A325BQ43264663-4D896422-44DC-4E26-839B-B1D792714FF6Q43284546-22096496-5AC1-4E37-B94A-EE55F8D1B2B1Q45761204-E671D3D5-9C12-4E76-AFFD-B8D571A1F717Q45935958-6CDE7CD4-9598-43B7-BD9B-0A63AD6823C7Q46352080-C47C3ADA-6398-4D58-9141-35F7C8ECA864Q46379979-AC46E836-2E2F-46B6-BC61-8554EB05301CQ48460124-456E66B1-B2A7-4EB0-A124-E92B97F3E315Q49503290-95103E1E-A193-4E5B-9BB8-17A2F34028CBQ51402660-CD01C659-5E63-4118-84B2-4B990303EEB3Q51432437-37E75B16-9505-43A1-AE54-43CFD54DC2DEQ52070431-F6EE5182-1CB3-4DB2-9EDA-1B2C44BBA997Q58217217-8CD4DE02-4A96-46E7-BC78-7F6839F52277Q63916819-28238659-E63F-424F-ACF1-8E30D01B9F97Q86393019-CB543C51-BAFD-422D-BF61-98A60B004FA0Q87542504-0B03B6F0-5E4A-4C6B-B2DD-A8F61E30BA1DQ89336517-5B564ED7-3BAB-4D03-A77F-B41D77862276Q89351978-A32C86A9-FA13-4441-BF2B-D76A9305FB06Q91762990-420D8859-0874-4FCA-9FB4-A37E5689D462Q92929093-69D267D4-435C-4D40-8EB9-4F119D4C06A3
P50
description
researcher
@en
wetenschapper
@nl
name
A Cleton
@en
A Cleton
@nl
type
label
A Cleton
@en
A Cleton
@nl
prefLabel
A Cleton
@en
A Cleton
@nl
P106
P31
P496
0000-0002-7413-8585